Search
Mebendazole
go.drugbank.com/drugs/DB00643ApprovedInvestigationalVet approvedA benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem]
Mixtures: L-OMBRIX-DUET, L-OMBRIX-DUETCategories: Heterocyclic Compounds, 2-RingCysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigationalCystinosis is a rare disease caused by mutations in the CTNS gene that encodes for cystinosin, a protein responsible for transporting cystine out of the cell lysosome. … [L15611] On August 25th 2020, the first ophthalmic solution for cystinosis requiring only 4 daily treatments was granted FDA approval.
Synonyms: 2-amino-1-ethanethiol, β-MEAProducts: CYSTAGON ® 150 MG, CYSTAGON ® 50 MG CAPSULASSodium oxybate
go.drugbank.com/drugs/DB09072ApprovedInvestigational[A18723] For safety reasons, sodium oxybate is a controlled substance only available through a restricted program in approved countries. … [L30598] It is a sodium salt of [gamma-Hydroxybutyric acid], an endogenous cerebral inhibitory neurotransmitter [A251445] and a metabolite of the inhibitory neurotransmitter GABA.
Products: Natriumoxybat Kalceks 500 mg/ml Lösung zum Einnehmen, Natriumoxybat neuraxpharm 500 mg/ml Lösung zum EinnehmenBrivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. … Briviact received FDA approval on February 19, 2016 [L760].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesProducts: BRIVIACT®10 MG, BRIRENTO® 100 MG TABLETASAvelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigationalAvelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. … [A261496] Avelumab was first approved by the FDA on March 23, 2017.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: BAVENCIO 200 MG/10 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 FLAKON, BAVENCIO®Panitumumab
go.drugbank.com/drugs/DB01269ApprovedInvestigationalPanitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent. … Panitumumab was granted FDA approval on 27 September 2006.[L17663]
Products: VECTIBIX® 20 MG/ ML, VECTIBIX 20 MG/ML 5 ML IV INFUZYON ICIN COZELTI ICEREN FLAKON, 1 ADETGemfibrozil
go.drugbank.com/drugs/DB01241ApprovedInvestigational[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. … Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsSynonyms: 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansäure, 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acidLevamisole
go.drugbank.com/drugs/DB00848ApprovedInvestigationalVet approvedWithdrawn[A178123] Interestingly, levamisole has been found as an adulterant in cocaine and can lead to a variety of adverse effects in individuals using this drug.[A178120] … [A178117] It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations[A178123] Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer.
Categories: Heterocyclic Compounds, 1-RingProducts: PVP- LEVAMISOLE POUR-ON SOLUTION 20 %w/v, PARAKS 40 MG/5 ML ŞURUP, 30 MLEptifibatide
go.drugbank.com/drugs/DB00063ApprovedInvestigationalDerived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.
Products: INTEGRILIN INYECTABLE 2 MG/ML., INTEGRILIN IV BOLUS INJECTION 2 mg/mlLetrozole
go.drugbank.com/drugs/DB01006ApprovedInvestigational[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. … Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: LETROZOLO EG, LETARA® 2.5 MG TABLETAS